Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acceleron Pharma, Inc.
Acceleron Introduces Breakthrough Program for Treatment of Anemia at the 27th Annual JP Morgan Healthcare Conference
January 30th, 2009
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, announced that it has designated a new development candidate, ACE-536, which selectively increases red blood cells and hemoglobin, as a potential treatment for anemia. ACE-536, like the Company’s lead development candidate ACE-011, utilizes a mechanism fundamentally different from existing therapies to increase hemoglobin levels. “We are extremely excited about ACE-536 because it represents an entirely new method of increasing hemoglobin and also demonstrates the tremendous potential of the GDF family...
Source: Health Business Week (2009-01-30)
|
